William Foster

Beaudry MM, Carignan D, Foster W, Lavallee MC, Aubin S, Lacroix F, Poulin E, Lachance B, Després P, Beaulieu L, Vigneault E, Martin AG

Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial

Clin Transl Radiat Oncol, 40 , 2023.

Résumé | Liens:

Bélanger C, Poulin É, Aubin S, Vigneault É, Martin AG, Foster W, Beaulieu L

Inter-observer evaluation of a GPU-based multicriteria optimization algorithm combined with plan navigation tools for HDR brachytherapy

Brachytherapy, 21 (4), 2022.

Résumé | Liens:

Lavoie-Gagnon H, Martin AG, Poulin E, Archambault L, Pilote L, Foster W, Vigneault E, Carignan D, Lacroix F

Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning

J Contemp Brachytherapy, 14 (1), 2022.

Résumé | Liens:

Pinthus JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, Siemens DR, Niazi T, Fradet V, Foster W, Duceppe E, Taussky D, Hamilton R, Lavallée L, Brown I, Chin J, Gopaul D, Wassef A, Kassouf W, Davis M, Violette PD, Agapay S, Balasubramanian K, Mian R, Rangarajan S, Sener A, Shayegan B, Devereaux PJ, Leong DP

Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy

J Urol, 207 (5), 2022.

Résumé | Liens:

Reynaud T, Hathout L, Carignan D, Barkati M, Martin AG, Foster W, Lacroix F, Delouya G, Taussky D, Morton G, Vigneault E

PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study

Brachytherapy, 20 (6), 2021.

Résumé | Liens:

Lavallée MC, Cantin A, Monéger F, Lefebvre M, Foster W, Vigneault E, Beaulieu L

Commissioning of an intra-operative US guided prostate HDR system integrating an EM tracking technology

Brachytherapy, 20 (6), 2021.

Résumé | Liens: